secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001171843-25-001491
Event type: regulatory
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose regains Nasdaq minimum bid price compliance; equity rule still breached
------------------------------------------------------------------------------

- Nasdaq confirmed closing bid price at or above $1.00 for 10 consecutive business days as of March 14, 2025.
- Aptose remains non-compliant with Nasdaq's $2.5M shareholders' equity requirement.
- Company operates under a Hearing Panel exception to regain equity compliance, but no assurance of success.
- Aptose is a clinical-stage precision oncology firm developing tuspetinib-based triple therapy for newly diagnosed AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325001491/0001171843-25-001491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325001491/f8k_031725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer